Affordable Access

Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties.

Authors
  • Cappelli, Andrea
  • Gallelli, Andrea
  • Manini, Monica
  • Anzini, Maurizio
  • Mennuni, Laura
  • Makovec, Francesco
  • Menziani, M Cristina
  • Alcaro, Stefano
  • Ortuso, Francesco
  • Vomero, Salvatore
Type
Published Article
Journal
Journal of medicinal chemistry
Publication Date
May 19, 2005
Volume
48
Issue
10
Pages
3564–3575
Identifiers
PMID: 15887964
Source
Medline
License
Unknown

Abstract

Novel arylpiperazine derivatives bearing lipophilic probes were designed, synthesized, and evaluated for their potential ability to interact with the 5-hydroxytryptamine(3) (5-HT(3)) receptor. Most of the new compounds show subnanomolar 5-HT(3) receptor affinity. Ester 6bc showing a picomolar K(i) value is one of the most potent 5-HT(3) receptor ligands so far synthesized. The structure-affinity relationship study suggests the existence of a certain degree of conformational freedom of the amino acid residues interacting with the substituents in positions 3 and 4 of the quipazine quinoline nucleus. Thus, the tacrine-related heterobivalent ligand 6o was designed in an attempt to capitalize on the evidence of such a steric tolerance. Compound 6o shows a nanomolar potency for both the 5-HT(3) receptor and the human AChE and represents the first example of a rationally designed high-affinity 5-HT(3) receptor ligand showing nanomolar AChE inhibitory activity. Finally, the computational analysis performed on compound 6o allowed the rationalization of the structure-energy determinants for AChE versus BuChE selectivity and revealed the existence of a subsite at the boundary of the 5-HT(3) receptor extracellular domain, which could represent a "peripheral" site similar to that evidenced in the AChE gorge.

Report this publication

Statistics

Seen <100 times